个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Song Jingru[1,2] * ; Huang Yanping[1,2,4] * ; Liu Lu[1,2] * ; Hui Dengcheng[1,2] ; Wang Zheng[2] ; Xie Dong[2] ; Jiang Yulang[1,2] ; Cao Hongyan[3] ; Dai Yancheng[3] ; Ye Guan[5] ; Su Shibing[2] ; Zhou Mingmei[2] ; Zhang Qin[4] ; Sun Mingyu[1,2] ;
机构： [1]Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China [2] Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China [3] Shanghai University of TCM, Shanghai TCM-integrated Hospital, China [4]Department of GCP,Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China [5]Central Research Institute, Shanghai Pharmaceuticals Holding Co.,Ltd., Shanghai 201203, China
出处：
DOI： 10.1016/j.jpba.2024.116513
ISSN：

关键词： Yinchenhao decoction Chronic hepatitis B Metabolomics Network pharmacology Bioinformatics

摘要：
Yinchenhao decoction (YCHD) is widely used in the treatment of damp-heat syndrome of chronic hepatitis B (CHB), but it remains unclear about the active compounds in YCHD and its potential mechanism for treating CHB. The purpose of this work is to evaluate the clinical efficacy of YCHD combined with nucleoside analogues (NAs) for the treatment of CHB. Besides, based on the exact clinical efficacy, we combined serum metabolomics and network pharmacology to screen differential metabolites and related pathways regulated by YCHD to investigate the possible mechanism for treating CHB. It revealed that NAs plus YCHD could significantly improve alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, increase HBV-DNA negative rate (P<0.05), reduce the levels of inflammatory factors and LSM (both P<0.05), regulate lipids (P<0.05), and improve the symptoms of traditional Chinese medicine (TCM) (P<0.05) in CHB patients. YCHD was relatively safe. It showed 30 active compounds including chlorogenic acid, geniposide, emodin, quercetin, kaempferol, β-sitosterol and aloe emodin, and 115 key targets which were related to the regulation of lipids and reduction of oxidative stress related to the effect of YCHD in CHB in the network pharmacology analysis. We found 9 core targets and 4 key metabolites according to metabolomics, which were partly consistent with the network pharmacology findings. It proved that network pharmacology combined with metabolomics can well explain the "multi-component-multi-target" mechanism of complex TCM.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

基金：
This work was supported by the major project of Shanghai Municipal S and T Commission (no. 19401972300), Shandong Province Key R&D Program (Major Science and Technology Innovation Project,2021CXGC010509), Key Laboratory of Chronic Deficiency Liver Disease of the State Administration of Traditional Chinese Medicine of the People’s Republic of China (20DZ2272200), Hangzhou Health and Health Commission(A20230658), Shanghai Key Specialty of Traditional Chinese Clinical Medicine(shslczdzk01201).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 3 区 医学
小类 | 2 区 分析化学 3 区 药学
JCR分区：
出版当年[2023]版：
Q2 CHEMISTRY, ANALYTICAL Q2 PHARMACOLOGY & PHARMACY
最新[2023]版：
Q2 CHEMISTRY, ANALYTICAL Q2 PHARMACOLOGY & PHARMACY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China [2] Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
共同第一作者：
通讯作者：
通讯机构： [1]Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China [2] Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
推荐引用方式(GB/T 7714)：
Song Jingru,Huang Yanping,Liu Lu,et al.Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B[J].Journal Of Pharmaceutical And Biomedical Analysis.2025,253:116513.doi:10.1016/j.jpba.2024.116513.
APA：
Song Jingru,Huang Yanping,Liu Lu,Hui Dengcheng,Wang Zheng...&Sun Mingyu.(2025).Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B.Journal Of Pharmaceutical And Biomedical Analysis,253,
MLA：
Song Jingru,et al."Integrated metabolomics and network pharmacology to explore the clinical efficacy and mechanism of Yinchenhao decoction combined with nucleoside analogues on chronic hepatitis B".Journal Of Pharmaceutical And Biomedical Analysis 253.(2025):116513

相关文献

[1]CCL20 and CD8A as potential diagnostic biomarkers for HBV-induced liver fibrosis in chronic hepatitis B [2]T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis [3]慢性乙型肝炎30年治疗与回顾 [4]慢性肝病社区管理的必要性和可行性分析 [5]Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma [6]A randomized phase 2b study of subcutaneous PD-L1 antibody ASC22 in virally-suppressed, HBeAg negative chronic hepatitis B patients [7]A noninvasive model discriminating significant histological changes in treatment-naive chronic hepatitis B patients with normal ALT [8]Peg-interferon alpha add-on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAg-positive chronic hepatitis B naive patients [9]A Network Pharmacology Study on the Molecular Mechanism of Protocatechualdehyde in the Treatment of Diabetic Cataract [10]Addendum: Increased Circulating T Follicular Helper Cells Induced via IL-12/21 in Patients With Acute on Chronic Hepatitis B Liver Failure.

资源点击量：21169 今日访问量：0 总访问量：1219 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)